ArticlePloS one2013
Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected].
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 55 citations in OpenAlex.
- Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial.AIDS research and therapy · 2022Trial
- Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.Journal of the International AIDS Society · 2017Trial
- Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study.AIDS (London, England) · 2014Trial
- CD8medRxiv : the preprint server for health sciences · 2025Article
- HIV and the gut: implications for HIV persistence, immune dysfunction and cure strategies.Frontiers in immunology · 2025Review
- Measuring Human Immunodeficiency Virus Reservoirs: Do We Need to Choose Between Quantity and Quality?The Journal of infectious diseases · 2024Review
- Venetoclax, alone and in combination with the BH3 mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized mice.Cell reports. Medicine · 2023Article
- Immune mobilising T cell receptors redirect polyclonal CD8Scientific reports · 2022Article
- Combination strategies to durably suppress HIV-1: Soluble T cell receptors.Journal of virus eradication · 2022Article
- Review
- Improved Detection of HIV Gag p24 Protein Using a Combined Immunoprecipitation and Digital ELISA Method.Frontiers in microbiology · 2021Article
- Transcriptional signature of resting-memory CD4 T cells differentiates spontaneous from treatment-induced HIV control.Journal of molecular medicine (Berlin, Germany) · 2020Article
- The multifaceted nature of HIV latency.The Journal of clinical investigation · 2020Review
- Next-Generation Sequencing in a Direct Model of HIV Infection Reveals Important Parallels to and Differences fromJournal of virology · 2020Article
- Measuring the Success of HIV-1 Cure Strategies.Frontiers in cellular and infection microbiology · 2020Review
- Membrane metalloprotease TRABD2A restricts HIV-1 progeny production in resting CD4Nature immunology · 2019Article
- Breaking the Glyco-Code of HIV Persistence and Immunopathogenesis.Current HIV/AIDS reports · 2019Review
- Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion.Nature communications · 2019Article
- Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection.PLoS pathogens · 2019Article
- New Frontiers in Measuring and Characterizing the HIV Reservoir.Frontiers in microbiology · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
Resting CD4+T cells infected with HIV persist in the presence of suppressive anti-viral therapy (ART) and are barriers to a cure. One potential curative approach, therapeutic vaccination, is fueled by recognition of the ability of a subset of elite controllers (EC) to control virus without therapy due to robust anti-HIV immune responses. Controllers have low levels of integrated HIV DNA and low levels of replication competent virus, suggesting a small reservoir. As our recent data indicates some reservoir cells can produce HIV proteins (termed GPR cells for Gag-positive reservoir cells), we hypothesized that a fraction of HIV-expressing resting CD4+T cells could be efficiently targeted and cleared in individuals who control HIV via anti-HIV cytotoxic T lymphocytes (CTL). To test this we examined if superinfected resting CD4+T cells from EC express HIV Gag without producing infectious virus and the susceptibility of these cells to CTL. We found that resting CD4+T cells expressed HIV Gag and were cleared by autologous CD8+T cells from EC. Importantly, we found the extent of CTL clearance in our in vitro assay correlates with in vivo reservoir size and that a population of Gag expressing resting CD4+T cells exists in vivo in patients well controlled on therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.